AI and cloud company MegaZone Cloud (CEO Dong-Hoon Yeom) announced on the 17th that it signed a business agreement (MOU) with AI new drug development specialist Eisenscience (CEO Jae-Woo Kang) for digital transformation in the new drug development field.
At the signing ceremony held at the Megazone Cloud Liaison Office in Yeoksam-dong, Seoul on the 16th, the two companies agreed to promote joint sales targeting pharmaceutical clients such as new drug development and clinical trial contract research organizations (CROs) and to cooperate in expanding the use of cloud-based AI.
Eigen Science is an AI-based new drug development company established through Korea University’s technology holding company. It focuses on developing small-molecule synthetic new drugs for intractable diseases using its own AI platform. Last year, it was selected for the Scale-up Tips program, which receives support from the Ministry of SMEs and Startups and private investment firms.
MegaZone Cloud provides high-performance GPU-based cloud infrastructure for the smooth operation of AIGEN Science's AI new drug development platforms 'AIGEN InSight' and 'AIGEN ChemTailor', and biomedical specialized language model 'Meerkat', and is responsible for operational support and technical consulting. AIGEN Science participates in the development of joint businesses in the pharmaceutical field based on its own AI technology.
The two companies plan to expand the scope of their cooperation by conducting various joint marketing activities such as seminars, conferences, and promotions, and sharing cloud operation experience and infrastructure optimization know-how.
“In order to improve the performance of AI-based new drug development, integrated design of technology and infrastructure is important,” said Jae-Woo Kang, CEO of Aizen Science. “Through cooperation with MegaZone Cloud, we will simultaneously secure industrial applicability and efficiency.”
MegaZone Cloud CEO Dong-Hoon Yeom said, “New drug development is one of the fields where AI technology is leading industrial change, and has great potential and ripple effects,” adding, “We will continue to expand our support for AI technology so that domestic new drug development companies can grow while implementing optimal technologies in a stable environment.”
- See more related articles
You must be logged in to post a comment.